Axcelead Drug Discovery Partners, Inc.’s Post

Examining the clinical use of engineered exosomes for therapeutic protein delivery: in this concise review, Chulhee Choi at ILIAS Biologics Inc. and collaborators discussed the challenges in developing exosomes as drug carriers and provided insights into strategies for their effective clinical translation https://lnkd.in/gTmHpiDe Additionally, they highlighted preclinical studies that have successfully used anti-inflammatory exosomes and suggested future directions for exosome therapeutics. An article also authored by Minseong Kim, Hojun Choi, Deok-Jin Jang, Hye-Jung Kim, Yujin Sub and Heon Yung Gee #extracellularvesicles #exosomes #bioengineering #drugdelivery #therapeutics #Vesiculab

Interested in learning about #flowcytometry? Watch our webinar on-demand to learn about the capabilities of this advanced technology.

JAX Study Director Aaron Rose explores how biological therapeutics are reshaping the traditional drug development process and why #humanizedmodels are essential for advancing biologics programs in this new JAX On-Demand video!

Watch our webinar on multiparameter flow cytometry to learn how this technology provides critical information in support of drug development.

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells, also called Tregs. Coya's combination biologics have already shown strong proof of concept data in ALS and Alzheimer's. Coya's lead candidate Coya 302 is the combination of low dose IL-2 and CTLA4-lg, synergistically enhancing Treg function and depletion of effector T cells and macrophages to further decrease inflammation, that can actually halt disease progression. Learn more about Coya's investigational therapies at coyatherapeutics.com. #CoyaTherapeutics #Tregs #Inflammation #Research #Development

Yihan L., a Senior Scientist at AbbVie, walks us through her teams latest poster: "A Novel in vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards." Yihan explains her team's innovative approach to pre-animal testing screening for biologics, focusing on stable molecule identification through precise incubation and LC-MS analysis. Discover how the use of internal standards, including NISTmAb and its Fc fragment, improve data accuracy and quality - promising findings that could transform biologics screening! https://bit.ly/3z7B1oK Rosendo Villafuerte-Vega, Hetal Sarvaiya #massspectrometry #glycosylation #oligonucleotides #vaccines #biotherapeutics #proteomics Dotmatics #biosimilars #cdmo

InMed's #pharmaceutical #pipeline includes three programs: -INM-901 for #Alzheimers disease demonstrates reduced #neuroinflammation and #amyloid-beta plaque and extension of #neurites in preclinical studies -INM-089 for age-related #macular degeneration #AMD improves photoreceptor function and thickness of outer nuclear layer of retina in preclinical studies -INM-755 for epidermolysis bullosa demonstrated enhanced anti-itch activity in a Phase 2 clinical study Learn about our pipeline: https://lnkd.in/gxceGUtK $INM #pharma #research

Are you attending #Tides2024 in Boston this week? 💡 We value your insights and invite you to join us at booth #419. James McAllister, Phil Shymanski and Brenda Karim are ready to explain how our PurePep solutions can elevate your peptide projects together. 💊Tow major trends transform the landscape of peptide therapeutics dramatically ⭐ Chemical or display screening platforms become state-of-the-art for target-based drug development, resulting in a significantly enriched preclinical pipeline. ⭐ The success of GLP-1 analogs for weight loss and obesity treatment is moon-shooting the pharmaceutical relevance of peptides, causing a shortage of external synthesis capacity. 👉🏽 The performance of novel drug development projects hinges on a seamless transition from screening to the clinics. A critical component is the synthetic in-house capability to rapidly scale up and improve peptide quality in parallel, along with the ability to adopt complex chemistry to advance the stability and efficacy of your lead compounds. ⏳ The clock is ticking. It's crucial to equip ourselves with the right manufacturing tools to stay ahead of the curve in peptide therapeutics. ' See you at booth #419.

Our very own Associate Director of CMC, Ashley Taylor, highlighted this article by LifeTein.com on the benefits of stapled peptides. Stapled peptides are breaking new ground in drug development, offering enhanced stability and efficacy for targeting previously undruggable interactions. What are your thoughts on the future of peptide therapeutics? Check out the article and let us know! https://lnkd.in/embS6_di #BiotechInnovation #PeptideTherapeutics #DrugDevelopment

#Primary_Cells Market Share Expected Huge Growth during 2023-2032 https://lnkd.in/dmXKXJke PromoCell Nucleome Therapeutics Lifeline Cell Technology RAMCON ImmunXperts, a Q² Solutions Company Primera Analytical Solutions Corporation Preferred Cell Systems™ Celprogen, Inc HCS Pharma ReachBio Research Labs Phasefocus Scintillant Bioscience Biopredic International StressMarq Biosciences Inc. BioNordika Denmark A/S Worthington Biochemical Corporation BioPharmaSpec Saguaro Technologies Bio Elpida Fluofarma ATLANTIC BONE SCREEN TargImmune Therapeutics AG Essent Biologics BioNordika Sweden AB Vitro Biopharma, Inc. LGC in partnership with ATCC Neuromics VITARIS AG Abalos Therapeutics GmbH CNS Pharmaceuticals, Inc. Evercyte GmbH Novabiosis, Inc. ION Biosciences Bioseek Innoprot ZenBio PELOBIOTECH GmbH SV Biotech BV Basilard BioTech, Inc. Cellanyx #Primary_Cells #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #primary #cells